期刊文献+

预激方案CAG治疗老年初治急性髓性细胞白血病的疗效 被引量:20

Therapeutic effect of priming induction regimen of CAG for newly diagnosed acute myeloid leukemia in elderly patients
下载PDF
导出
摘要 目的:评价含粒细胞集落刺激因子(granulocyte colony-stimulating factor,G-CSF)的CAG方案治疗老年初治急性髓性细胞白血病(AML)的疗效及不良反应。方法:75例老年初治AML分为CAG预激治疗组及常规方案化疗组,34例患者予以CAG预激方案治疗,41例患者予以常规吡柔比星+阿糖胞苷(TA)或高三尖杉脂碱+阿糖胞苷(HA)方案化疗,所有患者在第1疗程后间歇14d左右进行第2个疗程。结果:CAG预激治疗组2疗程完全缓解率为67.6%,总有效率达到82.4%,而常规化疗组2疗程的完全缓解率仅为39.0%,总有效率为56.1%;有预后差染色体核型的患者化疗疗效差,CAG预激治疗组的3年无病生存时间长于常规化疗组;CAG预激组除肌肉酸痛发生率较高外,其他血液系统及非血液系统的毒性和不良反应明显少于常规化疗组。结论:CAG预激方案治疗初治AML患者较之传统常规治疗具有化疗强度温和、敏感性好、完全缓解率及有效率高、毒副作用小,可以减少粒细胞缺乏恢复时间、减少合并感染率及增加幼稚细胞对化疗药物的敏感性等优点,推荐使用。 Objective To evaluate the clinical efficacy and toxicity of priming induction regimen of CAG for newly diagnosed acute myeloid leukemia (AML) in elderly patients. Methods Seventy-five patients with newly diagnosed AML were divided into 2 groups: 34 were treated with priming induction regimen CAG and the other 41 were treated with 2 classic routine chemotherapy regimens including pirarubicin+cytarabin ( TA ) and homoharringtonine + cytarabine ( HA ). All patients had a 14 day interval between the 2 courses of chemotherapy. Results The complete remission rate after 2 courses of induction therapy in patients with the priming induction regimen CAG and the total efficacy rate was significantly higher than that of the routine chemotherapy patients (67. 6% vs. 39 % ; 82.4 % vs. 56.1% ). Patients with unfavorable karyotypes had poor chemotherapy efficacy. The 3-year disease-free-survival(DFS) time was longer in patients with AML treated with priming induction regimen CAG than in patients treated with 2 classic routine chemotherapy regimens. Except for the muscular soreness, the hematological and non-hematological side effects in the CAG priming induction group were significantly fewer than those in the routine chemotherapy group. Conclusion The priming induction regimen of CAG has a significantly higher complete remission rate and an efficacy rate, fewer side effects, milder chemotherapy intensity and is more sensitive to chemotherapeutic drugs than those of the routine chemotherapy. It can shorten the duration of agranulocytosis and decrease infectious complications and increase the sensitivity of leukemia blast cells to chemotherapeutic drugs.
出处 《中南大学学报(医学版)》 CAS CSCD 北大核心 2008年第3期245-251,共7页 Journal of Central South University :Medical Science
关键词 老年性 急性髓性细胞白血病 粒细胞集落刺激因子 阿糖胞苷 阿克拉霉素 elderly acute myeloid leukemia granulocyte colony-stimulating factor cytarabine Aclarubincin
  • 相关文献

参考文献16

  • 1Kantarjian H, O'Brien S, Cortes J, et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: Predictive prognostic models for outcome [ J ]. Cancer, 2006, 106(5): 1090-1098.
  • 2Appelbaum F R, Gundacker H, Head D R, et al. Age and acute myeloid leukemia [ J ] . Blood, 2006 , 107 ( 9 ) 3481-3485.
  • 3Yamada K, Furusawa S, Saito K, et al. Concurrent use of granulocyte colony-stimulating factor previously treated acute myelogenous leukemia : a pilot study [ J ]. Leukemia, 1995 , 9(1):10-14
  • 4Mitelman F. ISCN ( 1995 ) : An International System for Human Cytogenetics Nomenclature ( H ) [ S ]. Basel: Karger, 1995.
  • 5Slovak M L, Kopecky K J, Cassileth P A, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia : a Southwest Oncology Group /Eastern Cooperative Oncology Group study [J]. Blood, 2000, 96(13) : 4075-4083.
  • 6Miller A B, Hoogstraten B, Staquet M, et al. Reporting resuits of cancer treatment [ J ] . Cancer, 1981 , 47 : 207- 214.
  • 7龙怡,杜欣,翁建宇,林伟.老年急性白血病45例临床分析[J].临床血液学杂志,2004,17(6):313-315. 被引量:12
  • 8李群华,杜欣,黄梓伦,罗成伟,钟立业,林伟.吡柔比星联合化疗治疗成人高危或难治复发急性白血病的评价[J].中华医学杂志,2005,85(17):1195-1197. 被引量:11
  • 9上海市白血病协作组.上海地区老年急性白血病417例回顾性研究[J].中华血液学杂志,1998,19(1):3-5. 被引量:83
  • 10欧阳建,白荣森.55例老年人急性白血病治疗观察[J].中华老年医学杂志,1996,15(4):211-213. 被引量:19

二级参考文献30

  • 1王俊英,魏丽华,王明琳.CAG方案在难治复发性急性髓系白血病中的应用[J].白血病.淋巴瘤,2004,13(6):361-362. 被引量:3
  • 2Godwin J E, Kopecky K J, Head D R, et al. A doubleblind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreatedacute myeloid leukemia:a Southwest Oncology Group study. Blood, 1998, 91:3607-3615.
  • 3Leith C P, Kpecky K J, Godwin J, et al. Acute myeloid leukemia in the elderly:a ssessment of multigrug resistance (MDR-1)and cytogenenties distinguishes biologic subgroups with remarkable distinct responses to standard chemotherapy: a Southwest Oncology G
  • 4Cassileth P A, Harrington D P, Appelbaum F R, et al. Chemotherapu compared with autologous or allogenenic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med, 1998, 339:1649-1656.
  • 5Estey E. Treatment of refractory AML. Leukemia, 1996, 10:932-932.
  • 6HIddeman W, Kern W, Schoch C, et al. Management of acute myeloid leukemia in elderly patients. J Clin Onc, 1999, 17:3569-3576.
  • 7Benzin J, Lang K, Earle C C, et al. The outcomes and costs of acute myeloid leukemia among the elderly. Arch Inter Med, 2002, 22:162:1597-1603.
  • 8杨天楹,中国实用内科杂志,1994年,14卷,515页
  • 9Liu Yinja,Br J Haematol,1991年,79卷,415页
  • 10团体著者,中华血液学杂志,1988年,9期,183页

共引文献149

同被引文献120

引证文献20

二级引证文献113

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部